- NZ reported 109,227 active cases of COVID-19 across the nation in the past 7 days.
- Fisher & Paykel expects an operating revenue between $1.675 billion and $1.7 billion for FY22.
- AFT partnered with Farmaforce Limited to provide the best representation to healthcare practitioners and professionals.
NZ reported 109,227 active cases of COVID-19 across the nation in the past 7 days with 17,192 new cases in the past 24 hours. Canterbury (18,389), Waikato (9,815) and Southern (8584) DHB reported the most cases on Tuesday. However, the 7-day rolling average of cases dropped on Tuesday to 15,565 from 17,020 on previous Tuesday.
The number of announced deaths from COVID-19 stood at 303.
Michael Plank from the University of Canterbury and Covid-19 Modelling Aotearoa expects the death rate to persist for some weeks with nearly 300-500 deaths after the first wave of Omicron ends.
Higher booster uptake among the elderly and younger people can be the best way of protection from Omicron as up-to-date vaccinations can lower the risk of being hospitalised, as per Ministry of Health.
Image Source: © 2022 Kalkine Media
Meanwhile, NZ implemented changes in COVID-19 rules over the weekend.
Amid this backdrop, let’s see how these 3 healthcare stocks have been doing so far.
Fisher & Paykel expects an operating revenue between $1.675 billion and $1.7 billion for FY22. FPH’s sales of OSA masks is tracking above the H1 growth rate despite supply issues but freight rates remain high in FY22, which may impact margin targets.
The business remains well positioned to add to positive changes in clinical practices and improve outcomes for respiratory patients in the long term.
On 29 March, at the time of writing, FPH was trading at $23.81, up 1.41%.
AFT Pharmaceuticals Limited (NZX:AFT)
AFT partnered with a contract sales organisation providing solutions to the Australian pharma industry, Farmaforce Limited, to provide the best representation to healthcare practitioners and professionals.
The partnership will strengthen AFT’s footprint in the Australian market and support the pharma company’s vision to give easy access to innovative products that help people.
On 29 March, at the time of writing, AFT was trading at $3.55, up 0.28%.
EBOS Group (NZX:EBO)
EBOS Group registered double-digit growth in earnings in FY22. This was propelled by robust revenue growth across Healthcare and Animal care segments.
The Group expects to complete LifeHealthcare’s acquisition before FY22 ends, subject to the satisfaction of certain conditions. EBO got approval from the Australian Competition and Consumer Commission (ACCC) for the acquisition on 24 March.
On 29 March, at the time of writing, EBO was trading at $40.22, up 0.55%.
NZ’s COVID-19 response has been effective with the lowest death rate across the world as lockdowns helped in eliminating the virus. However, as NZ reopens to travelers, more infections may hit the nation.
(NOTE: Currency is reported in NZ Dollar unless stated otherwise)